Abraxis says FDA OKs generic equivalent of Pfizer's injection

May 10 (Reuters) - Abraxis BioScience Inc. ABBI.O said it received approvals from the U.S. Food and Drug Administration to market several strengths of clindamycin injection, a generic version of Pfizer Inc.'s (PFE.N) Cleocin Phosphate injection.

The biopharmaceutical company said sales of clindamycin, used to treat serious infections, exceeded $16 million in the United States in 2006.

(Reporting by Amitha Rajan in Bangalore)

((Editing by Varsha Tickoo; Reuters Messaging: amitha.rajan.reuters.com@reuters.net; within U.S. +1 646 223 8780; outside U.S. +91-80-4135-5800)) Keywords: ABRAXISBIOSCIENCE FDA/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS1075